Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study of daratumumab in combination with pomalidonide and dexamethasone in multiple myeloma patients who are naive to treatment with or refractory to daratumumab alone, pomalidomide alone or to the combination of daratumumab and pomalidomide

Next Previous
Trial Profile

A retrospective study of daratumumab in combination with pomalidonide and dexamethasone in multiple myeloma patients who are naive to treatment with or refractory to daratumumab alone, pomalidomide alone or to the combination of daratumumab and pomalidomide

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Daratumumab (Primary) ; Pomalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use

    • Most Recent Events

    • 24 Jan 2017 New trial record
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top